Research and Markets: Global Melanoma Pipeline Review 2015
The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides ...
Business Wire (press release) - Fri, 27 Nov 2015 07:11

International Study Charts Genetic Trajectory for Melanoma
An international team of scientists has mapped out the genetic trajectories taken by melanoma as it evolves from early skin lesions (precursors) to malignant skin cancer, which can be lethal when it invades other tissues in the body. By tracing the ...
Oncology Nurse Advisor - Fri, 27 Nov 2015 06:03

FDA Okays First-line Nivolumab Alone in Melanoma
The US Food and Drug Administration (FDA) has expanded the indication for nivolumab (Opdivo, Bristol-Myers Squibb) to include its use as a single agent in the first-line treatment of unresectable or metastatic melanoma, the company announced today.
Medscape - Tue, 24 Nov 2015 09:26

FDA Approves Frontline Opdivo for Advanced Melanoma - Tue, 24 Nov 2015 06:03

Another First for Nivolumab: Approved as Frontline for BRaf Wild Type Melanoma Managed Markets Network - Tue, 24 Nov 2015 06:48

Opdivo Receives FDA Approval to Treat More Cases of Advanced Melanoma
P&T Community - Tue, 24 Nov 2015 10:45

FDA approves Opdivo to treat advanced form of kidney cancer - Mon, 23 Nov 2015 11:52

European Commission Approves Vemurafenib/Cobimetinib Combo for Melanoma
The European Commission (EC) has approved the combination of vemurafenib (Zelboraf) and cobimetinib (Cotellic) as a treatment for patients with BRAF-positive metastatic or unresectable melanoma, based on an extension in progression-free survival ...
OncLive - Wed, 25 Nov 2015 09:26

Roche's metastatic melanoma combo cleared in Europe
Seeking Alpha - Wed, 25 Nov 2015 06:48

EC approves Cotellic plus Zelboraf in advanced melanoma
European Pharmaceutical Review - Wed, 25 Nov 2015 07:45

Exelixis (EXEL) Announces EC Approval of COTELLIC Combo in BRAF V600 ... - Wed, 25 Nov 2015 06:37

Exelixis Receives European Approval on COTELLIC for Advanced Mutation-Positive ...
The - Wed, 25 Nov 2015 07:42

Exelixis Announces European Commission Approval of COTELLICâ„¢ (Cobimetinib ...
FierceBiotech - Wed, 25 Nov 2015 09:03

New Strategies but Modest Benefit in Uveal Melanoma
Uveal melanoma is a rare form of melanoma and is difficult to treat, with low response rates to therapies currently in use. Findings from two small studies that investigated two treatment strategies in patients with advanced disease show a hint of ...
Medscape - Mon, 23 Nov 2015 11:30

'Real-World' Melanoma Treatment Patterns Similar to Trials
Recent years have seen a revolution in the treatment of metastatic melanoma, with the introduction of both immunotherapy and targeted agents, but to date, only a limited number of studies have examined how these drugs are used in clinical practice.
Medscape - Tue, 24 Nov 2015 05:52

Oncolytic Immunotherapies Show Benefit in Combinations and as Single Agents in ...
In October 2015, the FDA approved talimogene laherparepvec (T-VEC; Imlygic) for the local treatment of unresectable cutaneous, subcutaneous, and nodal lesions in patients with melanoma recurrent after initial surgery. The approval was the first of its ...
OncLive - Wed, 25 Nov 2015 12:03

Scientists identify promising new melanoma drug
Melanoma in skin biopsy with H&E stain — this case may represent superficial spreading melanoma. Credit: Wikipedia/CC BY-SA 3.0. A new drug discovered by scientists at Sanford Burnham Prebys Medical Discovery Institute (SBP) may show promise for ...
Medical Xpress - Wed, 25 Nov 2015 01:22

Promising new melanoma drug in the offing
Times of India - Wed, 25 Nov 2015 21:37

1  2  3  4  5  6  7  8    ->

We do not evaluate or guarantee the accuracy of any content in this site. Click here for the full disclaimer.

Last update: September 2014